Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Amprenavir complexes with HIV-1 protease and its drug-resistant mutants altering hydrophobic clusters.

The FEBS journal - 1 Sept 2010

Shen Chen-Hsiang, Wang Yuan-Fang, Kovalevsky Andrey Y, Harrison Robert W, Weber Irene T

Abstract excerpt

The structural and kinetic effects of amprenavir (APV), a clinical HIV protease (PR) inhibitor, were analyzed with wild-type enzyme and mutants with single substitutions of V32I, I50V, I54V, I54M, I84V and L90M that are common in drug resistance. Crystal structures of the APV complexes at resolut...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carbamates
Share to Drug Resistance, Multiple, Viral
Share to Furans

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Protease

Share to HIV Protease Inhibitors

Share to Hydrophobic and Hydrophilic Interactions

Share to Molecular Conformation

Share to Saquinavir

Source

Open in PubMed Open full text

Identifiers

PMID: 20695887
DOI: 10.1111/j.1742-4658.2010.07771.x
PMCID: PMC2975871

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20695887-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Amprenavir complexes with HIV-1 protease and its drug-resistant mutants altering hydrophobic clusters.PMID 20695887Read ↗

Decoding drug resistant mechanism of V32I, I50V and I84V mutations of HIV-1 protease on amprenavir binding by using molecular dynamics simulations and MM-GBSA calculations.Semantic proximity Read ↗

Highly drug-resistant HIV-1 protease reveals decreased intra-subunit interactions due to clusters of mutations.Semantic proximity Read ↗

Energetic basis for drug resistance of HIV-1 protease mutants against amprenavir.Semantic proximity Read ↗

Effect of flap mutations on structure of HIV-1 protease and inhibition by saquinavir and darunavir.Semantic proximity Read ↗

Structural and kinetic analyses of the protease from an amprenavir-resistant human immunodeficiency virus type 1 mutant rendered resistant to saquinavir and resensitized to amprenavir.Semantic proximity Read ↗

Effects of drug-resistant mutations on the dynamic properties of HIV-1 protease and inhibition by Amprenavir and Darunavir.Semantic proximity Read ↗

Effects of the V82A and I54V mutations on the dynamics and ligand binding properties of HIV-1 protease.Semantic proximity Read ↗

Potent antiviral HIV-1 protease inhibitor GRL-02031 adapts to the structures of drug resistant mutants with its P1'-pyrrolidinone ring.Semantic proximity Read ↗

Drug Resistance Mutation L76V Alters Nonpolar Interactions at the Flap–Core Interface of HIV-1 ProteaseSemantic proximity Read ↗

Extreme multidrug resistant HIV-1 protease with 20 mutations is resistant to novel protease inhibitors with P1'-pyrrolidinone or P2-tris-tetrahydrofuran.Semantic proximity Read ↗

Insights into the interaction mechanism of first-generation HIV-1 protease inhibitors with wild-type and mutant (D30N and L76V) enzymes through in-silico based approach.Semantic proximity Read ↗

HIV-1 protease with 10 lopinavir and darunavir resistance mutations exhibits altered inhibition, structural rearrangements and extreme dynamics.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.